In an illustration of Jazz Pharmaceuticals plc’s focus on central nervous system disorders, the company recently presented 13 posters and oral presentations at the American Academy of Neurology annual meeting. The data, which largely buttress already-approved agents, ranged from describing the real-world impact of Xywav (calcium, magnesium, potassium and sodium oxybates) on idiopathic hypersomnia (IH) patients, to the long-term efficacy of its cannabis-derived Epidiolex (cannabidiol) on treatment-resistant epilepsies.
The data collectively paint a picture of a significant corporate shift, Phil Jochelson, Jazz’s neuroscience therapeutic head, told In Vivo.
